PubMed

Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.

Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H.

Diabetes Care. 2005 Nov;28(11):2728-32.PMID: 16249547 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.

Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K.

Am J Nephrol. 2006;26(1):82-6. Epub 2006 Mar 9.PMID: 16534182 [PubMed - indexed for MEDLINE]Related articles

Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia.

Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H.

Am J Nephrol. 2006;26(3):276-80. Epub 2006 Jun 13.PMID: 16772708 [PubMed - indexed for MEDLINE]Related articles

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria.

Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H.

Diabetes Metab Res Rev. 2006 Sep-Oct;22(5):385-9.PMID: 16506273 [PubMed - indexed for MEDLINE]Related articles

Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.

Nakamura T, Sugaya T, Node K, Ueda Y, Koide H.

Am J Kidney Dis. 2006 Mar;47(3):439-44.PMID: 16490622 [PubMed - indexed for MEDLINE]Related articles

Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis.

Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H.

Clin Nephrol. 2006 Jan;65(1):1-6.PMID: 16429835 [PubMed - indexed for MEDLINE]Related articles

Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.

Nakamura T, Fujiwara N, Sugaya T, Ueda Y, Koide H.

Metabolism. 2009 Aug;58(8):1185-90. Epub 2009 Jun 18.PMID: 19481229 [PubMed - indexed for MEDLINE]Related articles

Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease.

Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H.

Am J Med Sci. 2005 Oct;330(4):161-5.PMID: 16234607 [PubMed - indexed for MEDLINE]Related articles

Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease.

Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M.

J Lab Clin Med. 2004 Jan;143(1):23-30.PMID: 14749682 [PubMed - indexed for MEDLINE]Related articles

Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.

Am J Hypertens. 2007 Nov;20(11):1195-201.PMID: 17954367 [PubMed - indexed for MEDLINE]Related articles

Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.

Hofstra JM, Deegens JK, Steenbergen EJ, Wetzels JF.

Nephrol Dial Transplant. 2008 Oct;23(10):3160-5. Epub 2008 Apr 10.PMID: 18403431 [PubMed - indexed for MEDLINE]Related articles

Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy.

Nakamura T, Sugaya T, Ebihara I, Koide H.

Am J Nephrol. 2005 Sep-Oct;25(5):447-50. Epub 2005 Aug 23.PMID: 16118482 [PubMed - indexed for MEDLINE]Related articles

Urinary N-acetyl B glucosaminidase as an earlier marker of diabetic nephropathy and influence of low-dose perindopril/indapamide combination.

Basturk T, Altuntaş Y, Kurklu A, Aydin L, Eren N, Unsal A.

Ren Fail. 2006;28(2):125-8.PMID: 16538969 [PubMed - indexed for MEDLINE]Related articles

Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.

Nakamura T, Inoue T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H, Node K.

Clin Nephrol. 2008 Nov;70(5):385-92.PMID: 19000538 [PubMed - indexed for MEDLINE]Related articles

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.PMID: 14586737 [PubMed - indexed for MEDLINE]Related articles

Tubular and glomerular injury in diabetes and the impact of ACE inhibition.

Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P.

Diabetes Care. 2009 Sep;32(9):1684-8. Epub 2009 Jun 5.PMID: 19502542 [PubMed - indexed for MEDLINE]Related articlesFree article

Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.

Sasaki H, Kamijo-Ikemori A, Sugaya T, Yamashita K, Yokoyama T, Koike J, Sato T, Yasuda T, Kimura K.

Nephron Clin Pract. 2009;112(3):c148-56. Epub 2009 Apr 24.PMID: 19390215 [PubMed - indexed for MEDLINE]Related articles

Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion.

Nakamura T, Sugaya T, Koide H.

Shock. 2009 May;31(5):454-9.PMID: 18838948 [PubMed - indexed for MEDLINE]Related articles

Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria.

Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara L, Koide H.

Diabet Med. 2001 Apr;18(4):308-13.PMID: 11437862 [PubMed - indexed for MEDLINE]Related articles

Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride.

Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Ebihara I, Koide H.

Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):39-43.PMID: 15386824 [PubMed - indexed for MEDLINE]Related articles